TerminatedPhase 2NCT00003513

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Burzynski Research Institute
Principal Investigator
Stanislaw R. Burzynski, MD, PhD, M.D
Burzynski Research Institute
Intervention
Antineoplaston therapy (Atengenal + Astugenal)(drug)
Enrollment
3 enrolled
Eligibility
99 years · All sexes
Timeline
1996 – 1999

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00003513 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

See all trials for Neuroblastoma →

← Back to all trials